Literature DB >> 20662758

Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders.

Molly K Larson1, Elaine F Walker, Michael T Compton.   

Abstract

During recent decades, interest in the prevention of mental illnesses has increased. Improved diagnostic tools, the advent of atypical antipsychotic medications and the development of phase-specific psychosocial treatments have made intervention research in people at ultra-high risk for developing schizophrenia or a related psychotic disorder possible. Preliminary data suggest that low doses of atypical antipsychotic medications augmented by psychosocial treatments may delay the onset of psychosis in some individuals. Findings support further research for the establishment of best-practice standards.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662758      PMCID: PMC2930984          DOI: 10.1586/ern.10.93

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  112 in total

1.  Dimensions of premorbid functioning in schizophrenia: a review of neuromotor, cognitive, social, and behavioral domains.

Authors:  Lindsay S Schenkel; Steven M Silverstein
Journal:  Genet Soc Gen Psychol Monogr       Date:  2004-08

Review 2.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

3.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

Review 4.  Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.

Authors:  H Y Meltzer; P A Thompson; M A Lee; R Ranjan
Journal:  Neuropsychopharmacology       Date:  1996-03       Impact factor: 7.853

Review 5.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

6.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

Review 7.  Cognitive-behavioral therapy for schizophrenia: a review.

Authors:  Douglas Turkington; Robert Dudley; Debbie M Warman; Aaron T Beck
Journal:  J Psychiatr Pract       Date:  2004-01       Impact factor: 1.325

8.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

Review 9.  Developmentally moderated expressions of the neuropathology underlying schizophrenia.

Authors:  E F Walker
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

10.  IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis.

Authors:  Verity C Leeson; Thomas R E Barnes; Sam B Hutton; Maria A Ron; Eileen M Joyce
Journal:  Schizophr Res       Date:  2008-09-14       Impact factor: 4.939

View more
  44 in total

1.  Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency.

Authors:  Corina O Bondi; Ameer Y Taha; Jody L Tock; Nelson K B Totah; Yewon Cheon; Gonzalo E Torres; Stanley I Rapoport; Bita Moghaddam
Journal:  Biol Psychiatry       Date:  2013-07-25       Impact factor: 13.382

2.  Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.

Authors:  Olakunle James Onaolapo; Olayemi Quyyom Ademakinwa; Temitayo Opeyemi Olalekan; Adejoke Yetunde Onaolapo
Journal:  Psychopharmacology (Berl)       Date:  2017-06-14       Impact factor: 4.530

3.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

4.  The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis.

Authors:  Danielle M Moskow; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Tyrone D Cannon; Scott W Woods; Elaine F Walker
Journal:  Schizophr Res       Date:  2016-02-20       Impact factor: 4.939

5.  Encephalopathy or Psychosis?

Authors:  Malathi Latha Perugula; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2016-12-01

6.  Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Authors:  Masakuni Horiguchi; Kayleen E Hannaway; Adesewa E Adelekun; Karu Jayathilake; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

7.  Relationship between gender and psychotic symptoms in cocaine-dependent and methamphetamine-dependent participants.

Authors:  James J Mahoney; Rollin Y Hawkins; Richard De La Garza; Ari D Kalechstein; Thomas F Newton
Journal:  Gend Med       Date:  2010-10

Review 8.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

9.  Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials.

Authors:  Miguel Camacho-Gomez; Pere Castellvi
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

10.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.